JRCT ID: jRCTs031220744
Registered date:30/03/2023
A multicenter, single-arm trial to evaluate the efficacy and safety of vaccinia immune globulin therapy for patients with mpox or smallpox.
Basic Information
Recruitment status | Recruiting |
---|---|
Health condition(s) or Problem(s) studied | mpox or smallpox |
Date of first enrollment | 06/09/2023 |
Target sample size | 20 |
Countries of recruitment | |
Study type | Interventional |
Intervention(s) | VIG vaccinia immunoglobulin intravenous formulation is administered intravenously only once. |
Outcome(s)
Primary Outcome | Percentage of patients with a Ct value of 40 or higher on skin sample PCR testing at the site of the skin rash 14 days after study inclusion |
---|---|
Secondary Outcome | Virus mortality at 14 and 30 days after entry into the study Virus levels in blood, throat wipes, skin, and urine at 14, 21, 30, 60, and 120 days after inclusion Duration of fever of 37.5 or higher after entry into the study Adverse events since study entry General condition (bedridden, briefly bedridden, or completely bedridden) at study entry, 14 days, and 30 days after entry |
Key inclusion & exclusion criteria
Age minimum | >= 18age old |
---|---|
Age maximum | <= 65age old |
Gender | Both |
Include criteria | All 1)-3) must be satisfied. However, in the case of mpox, 4) and 5)must be also be satisfied. 1) Persons who have given written consent to participate in the research. 2) Persons who are at least 18 years old and less than 65 years old at the time of obtaining consent. 3) Persons diagnosed with Mpox or smallpox. However, smallpox shall be diagnosed when the pathogen is detected from a specimen such as a blister, pustule, crust, pharyngeal swab, or blood, and Mpox from a skin or mucosal lesion, blister content fluid, nasopharyngeal swab, pharyngeal swab, anorectal swab, other mucosal swab, blood, urine, or other materials appropriate for the test method, by the following methods, respectively The diagnosis is made when pathogens are detected in the following ways : Direct observation of virus particles by electron microscopy Detection of pathogens by separation and identification Detection of pathogen antigens by fluorescentantibody method Detection of pathogen genes by PCR 4) Those who will be treated with Tecovirimat in A multicenter, open-label, double-arm trial to evaluate the efficacy and safety of oral tecovirimat therapy for patients with mpox or smallpox . (hereafter referred to as the Tecopox study:jRCTs031220169). 5) Patients with severe mpox or severe high-risk mpox |
Exclude criteria | 1 Patients with a history of anaphylaxis or severe systemic reactions to human immunoglobulin products in the past 2 Persons with a history of selective IgA deficiency and the presence of anti-IgA antibodies 3 Persons with localized vaccinia keratitis 4 Persons who are deemed inappropriate for inclusion in the study by the principal investigator |
Related Information
Primary Sponsor | Morioka Shinichiro |
---|---|
Secondary Sponsor | Ohmagari Norio,Japan Agency for Medical Research and Development,Ministry of Health, Labour, and Welfare |
Source(s) of Monetary Support | |
Secondary ID(s) |
Contact
Public contact | |
Name | Sho Saito |
Address | 1-21-1 Toyama Shinjyuku-ku Tokyo Tokyo Japan 162-8655 |
Telephone | +81-3-3202-7181 |
ssaito@hosp.ncgm.go.jp | |
Affiliation | National Center for Global Health and Medicine |
Scientific contact | |
Name | Shinichiro Morioka |
Address | 1-21-1 Toyama Shinjyuku-ku Tokyo Tokyo Japan 162-8655 |
Telephone | +81-3-3202-7181 |
shmorioka@hosp.ncgm.go.jp | |
Affiliation | National Center for Global Health and Medicine |